<DOC>
	<DOC>NCT02988440</DOC>
	<brief_summary>A two part study to determine the maximum tolerated dose and/or recommended phase 2 dose of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma in first line. There will be a dose escalation part and a dose expansion part.</brief_summary>
	<brief_title>Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically or cytologically confirmed advanced (unresectable and/or metastatic) HCC Patients with advanced HCC not amenable for surgical or locoregional treatment At least one measureable tumor lesion that that has not been previously locally Patients with current cirrhotic status of ChildPugh class A only (56 points with total bilirubin &lt; 2 mg/dL for doseescalation) with no encephalopathy and no clinical ascites (ascites controlled by diuretics is also excluded in this study). Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Patient must meet required laboratory values at the screening Normal electrocardiogram at screening Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC Invasion of the main portal vein and/or tumor involvement in more than 50% of the liver (applicable only for the doseescalation part) Patients with Portalcaval shunts Prior or concomitant systemic anticancer treatment for advanced disease Systemic chronic steroid therapy (â‰¥ 10mg/day prednisone or equivalent) or any immunosuppressive therapy 7 days prior to planned date for first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids are allowed. Cardiac or cardiac repolarization abnormality Patients with active Hepatitis B infection (HBsAg positive) that are not receiving antiviral treatment are excluded Patients with positive test for hepatitis C ribonucleic acid (HCV RNA) Locoregional treatment within 4 weeks prior to initiation of study treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HCC</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Hepatocellular carcinoma (HCC)</keyword>
	<keyword>PDR001</keyword>
	<keyword>liver cancer</keyword>
	<keyword>immunotherapy liver</keyword>
	<keyword>malignant hepatoma</keyword>
	<keyword>Hepatocellular cancer</keyword>
	<keyword>advanced hepatocellular carcinoma (HCC)</keyword>
	<keyword>advanced liver cancer</keyword>
	<keyword>liver cancer progression</keyword>
	<keyword>sorafenib</keyword>
	<keyword>anti-PD1</keyword>
	<keyword>first line</keyword>
</DOC>